Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 in Subjects With Generalized Myasthenia Gravis

NCT06447597 is registered in ClinicalTrials.gov with Shanghai Jiaolian Drug Research and Development Co., Ltd as lead sponsor.

NCT NCT06447597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06447597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 in Subjects With Generalized Myasthenia Gravis
Lead sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase
Phase 2/3
Overall status
Recruiting
Start date
July 1, 2024
Completion date
December 30, 2026
Enrollment
104 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis